[go: up one dir, main page]

PT1847539E - Derivados de quinazolina - Google Patents

Derivados de quinazolina Download PDF

Info

Publication number
PT1847539E
PT1847539E PT07009390T PT07009390T PT1847539E PT 1847539 E PT1847539 E PT 1847539E PT 07009390 T PT07009390 T PT 07009390T PT 07009390 T PT07009390 T PT 07009390T PT 1847539 E PT1847539 E PT 1847539E
Authority
PT
Portugal
Prior art keywords
quinazoline derivatives
quinazoline
derivatives
Prior art date
Application number
PT07009390T
Other languages
English (en)
Inventor
Nicola Murdoch Heron
Andrew Austen Mortlock
Frederic Henri Jung
Georges Rene Pasquet
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT1847539E publication Critical patent/PT1847539E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509Six-membered rings
    • C07F9/6512Six-membered rings having the nitrogen atoms in positions 1 and 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT07009390T 2002-12-24 2003-12-22 Derivados de quinazolina PT1847539E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02293238 2002-12-24
EP03291315 2003-06-02

Publications (1)

Publication Number Publication Date
PT1847539E true PT1847539E (pt) 2009-10-06

Family

ID=32683824

Family Applications (2)

Application Number Title Priority Date Filing Date
PT07009390T PT1847539E (pt) 2002-12-24 2003-12-22 Derivados de quinazolina
PT03782672T PT1578755E (pt) 2002-12-24 2003-12-22 Derivados de fosfonooxiquinazolina e sua utilização farmacêutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT03782672T PT1578755E (pt) 2002-12-24 2003-12-22 Derivados de fosfonooxiquinazolina e sua utilização farmacêutica

Country Status (29)

Country Link
US (4) US7528121B2 (pt)
EP (2) EP1847539B1 (pt)
JP (3) JP4422102B2 (pt)
KR (1) KR101010299B1 (pt)
AR (2) AR042668A1 (pt)
AT (2) ATE370958T1 (pt)
AU (1) AU2003290313B2 (pt)
BR (1) BRPI0317717B8 (pt)
CA (1) CA2511613C (pt)
CL (1) CL2003002731A1 (pt)
CY (2) CY1107775T1 (pt)
DE (2) DE60315892T2 (pt)
DK (2) DK1578755T3 (pt)
ES (2) ES2329623T3 (pt)
IL (2) IL169112A (pt)
IS (2) IS2504B (pt)
MX (1) MXPA05006918A (pt)
MY (2) MY147761A (pt)
NO (2) NO335193B1 (pt)
NZ (1) NZ540698A (pt)
PL (2) PL223998B1 (pt)
PT (2) PT1847539E (pt)
RU (3) RU2357971C2 (pt)
SA (1) SA04240504B1 (pt)
SI (2) SI1578755T1 (pt)
TW (2) TWI393710B (pt)
UA (1) UA83814C2 (pt)
UY (1) UY28149A1 (pt)
WO (1) WO2004058781A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA82058C2 (uk) * 2001-12-24 2008-03-11 Астразенека Аб Заміщені похідні хіназоліну як інгібітори ауроракінази, спосіб їх одержання, фармацевтична композиція на їх основі
CA2508921A1 (en) * 2002-12-24 2004-07-15 Astrazeneca Ab Quinazoline compounds
US7528121B2 (en) 2002-12-24 2009-05-05 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use
CA2522079A1 (en) * 2003-04-16 2004-11-04 Astrazeneca Ab Quinazoline derivatives for treatment of cancer
AU2004247626B8 (en) * 2003-05-15 2011-05-19 Arqule, Inc. Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38
US20060135541A1 (en) * 2003-06-02 2006-06-22 Astrazeneca Ab (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
JP2007514759A (ja) 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
JP2008510734A (ja) 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
EP1802608A1 (en) * 2004-10-12 2007-07-04 AstraZeneca AB Quinazoline derivatives for use against cancer
WO2006040520A1 (en) * 2004-10-12 2006-04-20 Astrazeneca Ab Quinazoline derivatives
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
WO2006044869A1 (en) * 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
WO2007123892A2 (en) * 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
GB0609617D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
BRPI0719883A2 (pt) 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase
US20110136766A1 (en) * 2008-03-04 2011-06-09 Vitae Pharmaceuticals, Inc. Aurora kinase inhibitors
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
ES2616255T3 (es) 2008-04-30 2017-06-12 National Health Research Institutes Compuestos de pirimidina bicíclicos condensados como inhibidores de las aurora cinasas
JP2011526912A (ja) * 2008-07-03 2011-10-20 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング プロテインキナーゼ阻害剤としてのナフチリジノン
EP2361254A1 (en) * 2008-12-05 2011-08-31 ArQule, Inc. Raf inhibitors and their uses
EP2373326B1 (en) 2008-12-11 2016-03-09 Axcentua Pharmaceutucals AB Crystalline forms of genistein
US7863325B2 (en) 2008-12-11 2011-01-04 Axcentua Pharmaceuticals Ab Crystalline genistein sodium salt dihydrate
BRPI0923579A2 (pt) 2008-12-22 2020-01-14 Millennium Pharm Inc combinação de inibidores de aurora quinase e anticorpos anti-cd20
ES2609578T3 (es) 2011-03-04 2017-04-21 Glaxosmithkline Intellectual Property Development Limited Amino-quinolinas como inhibidores de quinasa
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基-喹啉類
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
BR112015019624A2 (pt) * 2013-02-21 2017-07-18 Glaxosmithkline Ip Dev Ltd quinazolinas como inibidores de quinase
HUE034490T2 (en) * 2013-09-16 2018-02-28 Astrazeneca Ab Therapeutic polymer nanoparticles and methods for their preparation and use
CN108530458A (zh) 2013-11-01 2018-09-14 卡拉制药公司 治疗化合物的结晶形式及其用途
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2015085289A1 (en) 2013-12-06 2015-06-11 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
JP2018524292A (ja) 2015-07-21 2018-08-30 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. オーロラキナーゼインヒビターと化学療法剤の投与
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
HUE066413T2 (hu) 2017-09-08 2024-08-28 Univ Leland Stanford Junior ENPP1 inhibitorok és alkalmazásuk rák kezelésére
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN112939948B (zh) * 2019-12-11 2022-05-17 苏州美诺医药科技有限公司 新型含喹唑啉类化合物及其中间体与应用
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
WO2022192139A1 (en) 2021-03-10 2022-09-15 Astrazeneca Ab Aurora kinase b inhibitors for use for treating cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
EP0584222B1 (en) 1991-05-10 1997-10-08 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
AU2737295A (en) 1994-06-09 1996-01-04 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (pt) 1994-11-12 1997-12-01 Zeneca Ltd
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2239692C (en) 1995-12-18 2008-12-16 Sugen, Inc. Diagnosis and treatment of aur-1 and/or aur-2 related disorders
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
BR9914326A (pt) * 1998-10-08 2001-06-26 Astrazeneca Ab Uso de um composto, composto, processo para a preparação do mesmo, composição farmacêutica, e, método para produzir um efeito antiangiogênico e/ou de redução da permeabilidade vascular em animais de sangue quente em necessidade de um tal tratamento
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
CZ20021009A3 (cs) 1999-09-21 2002-06-12 Astrazeneca Ab Deriváty chinazolinu, způsob jejich přípravy a jejich pouľití jako léčiv
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
WO2002000649A1 (en) * 2000-06-28 2002-01-03 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
WO2002008213A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
CA2426440C (en) * 2000-08-18 2011-03-15 Millennium Pharmaceuticals, Inc. Quinazoline derivatives as kinase inhibitors
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1408980A4 (en) * 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
GB0124299D0 (en) * 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
UA82058C2 (uk) * 2001-12-24 2008-03-11 Астразенека Аб Заміщені похідні хіназоліну як інгібітори ауроракінази, спосіб їх одержання, фармацевтична композиція на їх основі
CA2508921A1 (en) * 2002-12-24 2004-07-15 Astrazeneca Ab Quinazoline compounds
US7528121B2 (en) * 2002-12-24 2009-05-05 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use
CA2522079A1 (en) * 2003-04-16 2004-11-04 Astrazeneca Ab Quinazoline derivatives for treatment of cancer

Also Published As

Publication number Publication date
NO335193B1 (no) 2014-10-20
US20140162984A1 (en) 2014-06-12
TWI336327B (en) 2011-01-21
TWI393710B (zh) 2013-04-21
AU2003290313A1 (en) 2004-07-22
AU2003290313B2 (en) 2007-05-10
SI1847539T1 (sl) 2010-01-29
US9567358B2 (en) 2017-02-14
US20100069412A1 (en) 2010-03-18
PL223998B1 (pl) 2016-11-30
BR0317717A (pt) 2005-11-22
US20150307534A1 (en) 2015-10-29
JP2007326862A (ja) 2007-12-20
HK1111417A1 (en) 2008-08-08
KR20050088333A (ko) 2005-09-05
EP1847539B1 (en) 2009-08-05
PT1578755E (pt) 2007-10-19
IL169112A0 (en) 2009-02-11
IS8714A (is) 2008-02-13
JP4503090B2 (ja) 2010-07-14
CY1107775T1 (el) 2013-06-19
DK1847539T3 (da) 2009-11-09
DK1578755T3 (da) 2007-11-12
PL377680A1 (pl) 2006-02-06
SA04240504B1 (ar) 2008-04-01
NZ540698A (en) 2008-05-30
NO20052855D0 (no) 2005-06-13
ES2329623T3 (es) 2009-11-27
DE60328735D1 (de) 2009-09-17
SA04240504A (ar) 2005-12-03
IL185176A0 (en) 2007-12-03
IS7948A (is) 2005-07-20
US8268841B2 (en) 2012-09-18
NO20052855L (no) 2005-08-03
NO335446B1 (no) 2014-12-15
RU2005123485A (ru) 2006-03-10
EP1578755B1 (en) 2007-08-22
US20060116357A1 (en) 2006-06-01
EP1578755A1 (en) 2005-09-28
ES2290529T3 (es) 2008-02-16
CY1109479T1 (el) 2014-08-13
HK1080481A1 (en) 2006-04-28
DE60315892D1 (de) 2007-10-04
UA83814C2 (ru) 2008-08-26
BRPI0317717B1 (pt) 2017-12-19
TW201102369A (en) 2011-01-16
AR042668A1 (es) 2005-06-29
AR057753A2 (es) 2007-12-19
CL2003002731A1 (es) 2005-01-07
WO2004058781A1 (en) 2004-07-15
JP4422102B2 (ja) 2010-02-24
IL169112A (en) 2010-12-30
UY28149A1 (es) 2004-07-30
MXPA05006918A (es) 2005-08-18
ATE370958T1 (de) 2007-09-15
BRPI0317717B8 (pt) 2021-05-25
PL221490B1 (pl) 2016-04-29
KR101010299B1 (ko) 2011-01-25
SI1578755T1 (sl) 2007-12-31
DE60315892T2 (de) 2008-08-14
US7528121B2 (en) 2009-05-05
IL185176A (en) 2011-10-31
IS2504B (is) 2009-04-15
RU2350611C1 (ru) 2009-03-27
JP2006512418A (ja) 2006-04-13
US9018191B2 (en) 2015-04-28
JP4906608B2 (ja) 2012-03-28
JP2009046514A (ja) 2009-03-05
EP1847539A1 (en) 2007-10-24
MY147761A (en) 2013-01-31
CA2511613A1 (en) 2004-07-15
CA2511613C (en) 2012-10-02
MY136174A (en) 2008-08-29
TW200510342A (en) 2005-03-16
RU2357971C2 (ru) 2009-06-10
RU2007121850A (ru) 2008-12-20
IS2884B (is) 2014-06-15
NO20131444L (no) 2005-08-03
PL412704A1 (pl) 2015-10-12
ATE438644T1 (de) 2009-08-15

Similar Documents

Publication Publication Date Title
GB0215823D0 (en) Quinazoline derivatives
PT1847539E (pt) Derivados de quinazolina
GB0322409D0 (en) Quinazoline derivatives
IL174534A0 (en) Quinazoline derivatives
GB0321648D0 (en) Quinazoline derivatives
IL174284A0 (en) Quinazoline derivatives
IL174257A0 (en) Quinazoline derivatives
AP1850A (en) Spiroindolineplperidine derivatives
EG24050A (en) Heterocylocarboxamide derivatives
SI1474420T1 (sl) Spojine kinazolina
EP1522540A4 (en) AZAARENE DERIVATIVES
IL174390A0 (en) Quinazoline derivatives
GB0326459D0 (en) Quinazoline derivatives
GB0330002D0 (en) Quinazoline derivatives
PL377474A1 (pl) Pochodne 3H-chinazolin-4-onu
GB2410025B (en) Quinazolin-4-one derivatives
AU2003222659A8 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
PL374817A1 (en) Quinazoline derivatives
GB0321621D0 (en) Quinazoline derivatives
EP1531854A4 (en) O-DERIVATED NOCATHIACIN DERIVATIVES
GB0321620D0 (en) Quinazoline derivatives
GB0213488D0 (en) 2-Naphthamide derivatives
AU2003243397A8 (en) Homo-camptothecin derivatives
GB0215825D0 (en) Quinazoline derivatives
AU2003290279A1 (en) Quinazoline derivatives